<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d231">
    <sentence id="DDI-DrugBank.d231.s0" text="Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.">
        <entity id="DDI-DrugBank.d231.s0.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s0.e1" charOffset="50-75"
            type="group" text="aminoglycoside antibiotics"/>
        <pair id="DDI-DrugBank.d231.s0.p0" e1="DDI-DrugBank.d231.s0.e0"
            e2="DDI-DrugBank.d231.s0.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s1" text="Except in life-threatening situations, avoid this combination."/>
    <sentence id="DDI-DrugBank.d231.s2" text="Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.">
        <entity id="DDI-DrugBank.d231.s2.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s2.e1" charOffset="49-63"
            type="drug" text="ethacrynic acid"/>
        <pair id="DDI-DrugBank.d231.s2.p0" e1="DDI-DrugBank.d231.s2.e0"
            e2="DDI-DrugBank.d231.s2.e1" ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s3" text="Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.">
        <entity id="DDI-DrugBank.d231.s3.e0" charOffset="33-43"
            type="group" text="salicylates"/>
        <entity id="DDI-DrugBank.d231.s3.e1" charOffset="64-73"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s3.e2" charOffset="116-125"
            type="group" text="salicylate"/>
        <pair id="DDI-DrugBank.d231.s3.p0" e1="DDI-DrugBank.d231.s3.e0"
            e2="DDI-DrugBank.d231.s3.e1" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d231.s3.p1" e1="DDI-DrugBank.d231.s3.e0"
            e2="DDI-DrugBank.d231.s3.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s3.p2" e1="DDI-DrugBank.d231.s3.e1"
            e2="DDI-DrugBank.d231.s3.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s4" text="Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.">
        <entity id="DDI-DrugBank.d231.s4.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s4.e1" charOffset="79-90"
            type="drug" text="tubocurarine"/>
        <entity id="DDI-DrugBank.d231.s4.e2" charOffset="125-139"
            type="drug" text="succinylcholine"/>
        <pair id="DDI-DrugBank.d231.s4.p0" e1="DDI-DrugBank.d231.s4.e0"
            e2="DDI-DrugBank.d231.s4.e1" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d231.s4.p1" e1="DDI-DrugBank.d231.s4.e0"
            e2="DDI-DrugBank.d231.s4.e2" ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d231.s4.p2" e1="DDI-DrugBank.d231.s4.e1"
            e2="DDI-DrugBank.d231.s4.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s5" text="Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.">
        <entity id="DDI-DrugBank.d231.s5.e0" charOffset="0-6"
            type="drug" text="Lithium"/>
        <entity id="DDI-DrugBank.d231.s5.e1" charOffset="43-51"
            type="group" text="diuretics"/>
        <entity id="DDI-DrugBank.d231.s5.e2" charOffset="73-79"
            type="drug" text="lithium"/>
        <entity id="DDI-DrugBank.d231.s5.e3" charOffset="121-127"
            type="drug" text="lithium"/>
        <pair id="DDI-DrugBank.d231.s5.p0" e1="DDI-DrugBank.d231.s5.e0"
            e2="DDI-DrugBank.d231.s5.e1" ddi="true" type="advise"/>
        <pair id="DDI-DrugBank.d231.s5.p1" e1="DDI-DrugBank.d231.s5.e0"
            e2="DDI-DrugBank.d231.s5.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s5.p2" e1="DDI-DrugBank.d231.s5.e0"
            e2="DDI-DrugBank.d231.s5.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s5.p3" e1="DDI-DrugBank.d231.s5.e1"
            e2="DDI-DrugBank.d231.s5.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s5.p4" e1="DDI-DrugBank.d231.s5.e1"
            e2="DDI-DrugBank.d231.s5.e3" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s5.p5" e1="DDI-DrugBank.d231.s5.e2"
            e2="DDI-DrugBank.d231.s5.e3" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s6" text="Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.">
        <entity id="DDI-DrugBank.d231.s6.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s6.e1" charOffset="68-89"
            type="group" text="antihypertensive drugs"/>
        <pair id="DDI-DrugBank.d231.s6.p0" e1="DDI-DrugBank.d231.s6.e0"
            e2="DDI-DrugBank.d231.s6.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s7" text="Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.">
        <entity id="DDI-DrugBank.d231.s7.e0" charOffset="25-34;50-74"
            type="group" text="ganglionic adrenergic blocking drugs"/>
        <entity id="DDI-DrugBank.d231.s7.e1" charOffset="39-74"
            type="group" text="peripheral adrenergic blocking drugs"/>
        <pair id="DDI-DrugBank.d231.s7.p0" e1="DDI-DrugBank.d231.s7.e0"
            e2="DDI-DrugBank.d231.s7.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s8" text="Furosemide may decrease arterial responsiveness to norepinephrine.">
        <entity id="DDI-DrugBank.d231.s8.e0" charOffset="0-9"
            type="drug" text="Furosemide"/>
        <entity id="DDI-DrugBank.d231.s8.e1" charOffset="51-64"
            type="drug" text="norepinephrine"/>
        <pair id="DDI-DrugBank.d231.s8.p0" e1="DDI-DrugBank.d231.s8.e0"
            e2="DDI-DrugBank.d231.s8.e1" ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s9" text="However, norepinephrine may still be used effectively.">
        <entity id="DDI-DrugBank.d231.s9.e0" charOffset="9-22"
            type="drug" text="norepinephrine"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s10" text="Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.">
        <entity id="DDI-DrugBank.d231.s10.e0" charOffset="39-48"
            type="drug" text="sucralfate"/>
        <entity id="DDI-DrugBank.d231.s10.e1" charOffset="54-63"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s10.e2" charOffset="132-141"
            type="drug" text="furosemide"/>
        <pair id="DDI-DrugBank.d231.s10.p0"
            e1="DDI-DrugBank.d231.s10.e0" e2="DDI-DrugBank.d231.s10.e1"
            ddi="true" type="effect"/>
        <pair id="DDI-DrugBank.d231.s10.p1"
            e1="DDI-DrugBank.d231.s10.e0" e2="DDI-DrugBank.d231.s10.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s10.p2"
            e1="DDI-DrugBank.d231.s10.e1" e2="DDI-DrugBank.d231.s10.e2" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s11" text="Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.">
        <entity id="DDI-DrugBank.d231.s11.e0" charOffset="128-137"
            type="drug" text="furosemide"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s12" text="The intake of furosemide and sucralfate should be separated by at least two hours.">
        <entity id="DDI-DrugBank.d231.s12.e0" charOffset="14-23"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s12.e1" charOffset="29-38"
            type="drug" text="sucralfate"/>
        <pair id="DDI-DrugBank.d231.s12.p0"
            e1="DDI-DrugBank.d231.s12.e0" e2="DDI-DrugBank.d231.s12.e1"
            ddi="true" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s13" text="Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.">
        <entity id="DDI-DrugBank.d231.s13.e0" charOffset="101-110"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s13.e1" charOffset="116-135"
            type="drug" text="acetylsalicylic acid"/>
        <pair id="DDI-DrugBank.d231.s13.p0"
            e1="DDI-DrugBank.d231.s13.e0" e2="DDI-DrugBank.d231.s13.e1"
            ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s14" text="There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.">
        <entity id="DDI-DrugBank.d231.s14.e0" charOffset="130-139"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s14.e1" charOffset="170-175"
            type="group" text="NSAIDs"/>
        <pair id="DDI-DrugBank.d231.s14.p0"
            e1="DDI-DrugBank.d231.s14.e0" e2="DDI-DrugBank.d231.s14.e1"
            ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s15" text="Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.">
        <entity id="DDI-DrugBank.d231.s15.e0" charOffset="53-64"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d231.s15.e1" charOffset="125-134"
            type="drug" text="furosemide"/>
        <pair id="DDI-DrugBank.d231.s15.p0"
            e1="DDI-DrugBank.d231.s15.e0" e2="DDI-DrugBank.d231.s15.e1"
            ddi="true" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s16" text="Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.">
        <entity id="DDI-DrugBank.d231.s16.e0" charOffset="0-11"
            type="drug" text="Indomethacin"/>
    </sentence>
    <sentence id="DDI-DrugBank.d231.s17" text="Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.">
        <entity id="DDI-DrugBank.d231.s17.e0" charOffset="24-35"
            type="drug" text="indomethacin"/>
        <entity id="DDI-DrugBank.d231.s17.e1" charOffset="41-50"
            type="drug" text="furosemide"/>
        <entity id="DDI-DrugBank.d231.s17.e2" charOffset="150-159"
            type="drug" text="furosemide"/>
        <pair id="DDI-DrugBank.d231.s17.p0"
            e1="DDI-DrugBank.d231.s17.e0" e2="DDI-DrugBank.d231.s17.e1"
            ddi="true" type="advise"/>
        <pair id="DDI-DrugBank.d231.s17.p1"
            e1="DDI-DrugBank.d231.s17.e0" e2="DDI-DrugBank.d231.s17.e2" ddi="false"/>
        <pair id="DDI-DrugBank.d231.s17.p2"
            e1="DDI-DrugBank.d231.s17.e1" e2="DDI-DrugBank.d231.s17.e2" ddi="false"/>
    </sentence>
</document>
